Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

Ninth European International Kidney Cancer Symposium

25 - 26 Apr 2014

Dublin, Dublin, Ireland

Optimising metastic renal cell carcinoma (mRCC): Treatment lessons from the...

Dr Thomas Hutson - Baylor University Medical Center, Dallas, USA

Optimising metastic renal cell carcinoma (mRCC): Treatment lessons from the real world: Introduction ( Dr Thomas Hutson - Baylor University Medical Center, Dallas, USA )

Additional treatment options impact first-line treatment of mRCC: No

Prof Stéphan Oudard - Hôpital Européen Georges Pompidou, Paris, France

Additional treatment options impact first-line treatment of mRCC: No ( Prof Stéphan Oudard - Hôpital Européen Georges Pompidou, Paris, France )

Current treatment options in mRCC

Dr Thomas Hutson - Baylor University Medical Center, Dallas, USA

Current treatment options in mRCC ( Dr Thomas Hutson - Baylor University Medical Center, Dallas, USA )

Discussion: Additional treatment options impact first-line treatment of mRCC

Dr Thomas Hutson; Prof Stéphan Oudard; Prof Patrick Schöffski; Dr Ignacio Durán

Discussion: Additional treatment options impact first-line treatment of mRCC ( Dr Thomas Hutson; Prof Stéphan Oudard; Prof Patrick Schöffski; Dr Ignacio Durán )

Additional treatment options impact first-line treatment of mRCC: Yes

Prof Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium

Additional treatment options impact first-line treatment of mRCC: Yes ( Prof Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium )

What have we learned? Expert perspectives

Dr Thomas Hutson; Prof Stéphan Oudard; Prof Patrick Schöffski; Dr Ignacio Durán

What have we learned? Expert perspectives ( Dr Thomas Hutson; Prof Stéphan Oudard; Prof Patrick Schöffski; Dr Ignacio Durán )

From clinical trial to clinical practice: Evidence from the real world

Dr Ignacio Durán - Associate Director of Clinical Research at START Madrid...

From clinical trial to clinical practice: Evidence from the real world ( Dr Ignacio Durán - Associate Director of Clinical Research at START Madrid, Madrid, Spain )

Gene targeting in kidney cancer treatment

Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France

Gene targeting in kidney cancer treatment ( Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France )

Surgical strategies available for renal cell carcinoma with inferior vena cava...

Prof Christopher G. Wood - The University of Texas MD Anderson Cancer Center...

Surgical strategies available for renal cell carcinoma with inferior vena cava invasion ( Prof Christopher G. Wood - The University of Texas MD Anderson Cancer Center, Houston, USA )

Use of robotics in kidney cancer surgery

Dr Christophe Vaessen - Groupe Hospitalier Pitié-Salpêtrière, Paris, France

Use of robotics in kidney cancer surgery ( Dr Christophe Vaessen - Groupe Hospitalier Pitié-Salpêtrière, Paris, France )

Work and history of the Kidney Cancer Association

Carrie Konosky - Vice President of Development & Public Affairs, Kidney Cancer...

Work and history of the Kidney Cancer Association ( Carrie Konosky - Vice President of Development & Public Affairs, Kidney Cancer Association, Chicago, USA )

Intratumour heterogeneity in renal and lung cancer

Prof Charles Swanton - CRUK London Research Institute and UCL, London, UK

Intratumour heterogeneity in renal and lung cancer ( Prof Charles Swanton - CRUK London Research Institute and UCL, London, UK )

Kidney cancer treatment ten years from now

Prof Martin Gore - The Royal Marsden Hospital, London, UK

Kidney cancer treatment ten years from now ( Prof Martin Gore - The Royal Marsden Hospital, London, UK )

More from ecancer